(redirected from Kaplan-Meier Survival Analysis)
KMSAKonica Minolta Sensing Americas, Inc. (Ramsey, NJ)
KMSAKomatsu Marketing Support Australia
KMSAKonica Minolta South Africa (Bidvest Group)
KMSAKaplan-Meier Survival Analysis (statistical analysis method)
KMSAKey Management System Agent
KMSAKorea Motor Sport Association
KMSAKia Motors South Africa (automobiles)
References in periodicals archive ?
Kaplan-Meier survival analysis was conducted in R Studio 3.3.2 using the "survival" and "survminer" packages to determine survival probabilities over time for each salinity treatment, as well as median survival times (i.e., time in days at which survival probability is 0.5).
Kaplan-Meier survival analysis was also performed for perineural invasion, which did not show significant differences (HR of no perineural invasion, 0.8243; 95% CI, 0.4642-1.441; p=0.4862; Figure 2C).
Kaplan-Meier survival analysis was conducted to compare the tumour stage and its effect on the overall survival.
The survival difference between two groups was statistically significant with Kaplan-Meier survival analysis (P < 0.001).
Kaplan-Meier survival analysis of all 119 THAs, considering revision for any reason as the primary endpoint, indicated an 8-year survival rate of 97.3% for the acetabular component and 100% for the femoral component (Fig.
The Kaplan-Meier survival analysis showed a statistically significant difference in disease-free survival between the two subgroups (85.54% vs.
Enakpene and his colleagues used Kaplan-Meier survival analysis to look at pregnancy latency over time for women who did--or didn't--receive a cerclage.
This is clearly shown in Kaplan-Meier survival analysis in Table-III and the Fig.3 explains the survival plot.
The relationship between prognostic factors and outcomes was modeled using univariate Kaplan-Meier survival analysis. Statistical comparisons were performed using the Kaplan-Meier method with the log-rank test.
Kaplan-Meier Survival Analysis. Median survival (95% CI) for each treatment group of A, B, and C was 2.75 (0.055.45), 2.88 (1.46-4.30), and 9.87 years (2.56-17.18), respectively.
Supplementary Figure 4A: Kaplan-Meier survival analysis of the time to PSA relapse after radical prostatectomy in the Taylor patient cohort (n=130) [20]; Kaplan-Meier analysis of the biochemical recurrence (BCR) free survival of the CAPRA* score categories.